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Whole protein mass spectrometry
Background: Fibrinogen is an acute phase glycoproteinwhose concentration increases in response to trauma. The
newly synthesised protein is functionally enhanced and it is known that treatmentwith neuraminidase increases
the rate of ﬁbrin polymerisation. To explore this, we examined the differences between the oligosaccharide
structures of quiescent and acute phase ﬁbrinogen.
Methods: A series of plasma samples was obtained from two individuals suffering an acute phase response.
Fibrinogen chainswere examined directly by ESImass spectrometry before and after digestionwith N-glycosidase
F and β1,4 galactosidase.
Results: The Bβ and γ chains of acute phase ﬁbrinogen showed amass decrease of 162 Da (Gal) in some 50% of the
molecules, and the Bβ chain showed an additional decrease corresponding to a further loss of NAcGlc. Incubation
withN-glycosidase F normalised all isoformmasses to that of the quiescent naked protein, conﬁrming theN-linked
oligosaccharide as the source of heterogeneity. β1,4 galactosidase treatment showed the structural difference was
the absence of the penultimate Gal from the biantennary oligosaccharides, and mapping of tryptic glycopeptides
conﬁrmed these results showing that approximately half the chains lacked Gal.
Conclusions and implications: The failure of incorporation Gal excludes the possibility of the hepatic NAcNeu Gal
transferase capping the oligosaccharides with sialic acid. This has two desirable haemostatic outcomes: ﬁbrin
monomers will polymerise and form clots more rapidly, and two galactose residues can never be exposed
diminishing uptake of the protein by the asialoglycoprotein receptor and ramping up concentration at a time of
challenge.© 2015 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fibrinogen is an acute phase glycoprotein that on activation by
thrombin polymerises to form a mesh that binds activated platelets
and stems blood loss from sites of injury. Correct clot formation and
ultimate ﬁbrin dissolution (ﬁbrinolysis) are quite literally matters of
life or death. Fibrinogen, a 340 kDa glycoprotein, is synthesised in the
liver from individual Aα, Bβ and γ chains [1]. Initially, a signal peptide
directs the nascent chains into the endoplasmic reticulum where core
glycosylation occurs. Following cleavage of the leader sequence, the
mature protein is assembled from Aα-γ and Bβ-γ intermediates [2].
After acquiring an additional Bβ or Aα chain, Aα-Bβ-γ half-molecules
dimerise and the (Aα-Bβ-γ)2 assembly proceeds to the Golgi for
pruning and extension of its N-linked oligosaccharides before ﬁnal
secretion into the circulation.
The Bβ and γ chains each contain a single N-linked oligosaccharide
side chain attached to Asn364 and Asn52, respectively. Thesestchurch 8014, New Zealand.
. This is an open access article understructures, -NAcGlc2-Man-(Man-NAcGlc-Gal-NAcNeu)2, are exclu-
sively biantennary and terminate with sialic acid (NAcNeu) [3,4].
This means each 340 kDa ﬁbrinogen molecule can have a maximum
of eight sialic acids; however, partial in vivo desialylation ensures an
average of only ~5 mol/mol of circulating ﬁbrinogen [5]. The precise
conﬁguration of the terminal sugars is however important in deter-
mining the ﬁbrin polymerisation rate and the circulatory half-life of
ﬁbrinogen. Electrostatic repulsion from negatively charged sialic
acid residues delays ﬁbrin polymerisation and clot formation [6],
and exposure of galactose terminals appears to initiate uptake by
the asialoglycoprotein receptor [7] as no circulating ﬁbrinogen mol-
ecules have been ever found that lack both sialic acid residues [8].
Different physiological stresses are known to modulate the carbohy-
drate structure of ﬁbrinogen. In liver disease, increased sialic acid
content extends thrombin clotting time [6], and during pregnancy
[9], where there is an increased risk of haemorrhage, sialic acid satu-
ration decreases shortening the clotting time.
The acute phase response has a profound effect not only on the
concentration but also on the structure of plasma proteins. For example,
in the case of α1 antitrypsin, another liver derived glycoprotein [10],
there is a shift tomore highly branched triantennary structures, therebythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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plasma has been shown to contain more high-molecular weight
(HMW) ﬁbrinogen (340 kDa) than LMW ﬁbrinogen (305 kDa) with
one of its αC domain cleaved off [11]. The increase in the proportion
of HMW ﬁbrinogen accompanying an acute phase is however a conse-
quence of the increased rate of ﬁbrinogen synthesis. Since this α chain
cleavage occurs in circulation, LMW ﬁbrinogen simply represents an
older population of molecules. Similarly, the higher level of Aα chain
phosphorylation associatedwith an inﬂammatory response [12] reﬂects
larger numbers of newer molecules in the plasma pool [13].
Bleeding after surgery is a serious complication associated with
increased morbidity and mortality [14]. The acute phase response
causes endogenous ﬁbrinogen levels to typically double 24 h after
surgery [15]. The functionality of this newly synthesised ﬁbrinogen is
enhanced as evidenced by the increase seen in the ratio of functional
(Clauss) to physical (total clottable) ﬁbrinogen [15]; hence, the acute
phase not only produces more ﬁbrinogen but it is better conﬁgured
for its function. Because of the inherent importance of the carbohydrate
structure to the function and concentration of plasma proteins [16], we
decided to determine the oligosaccharide structures of ﬁbrinogen mol-
ecules synthesised during an acute phase response and compare them
to quiescent state structures.
2. Materials and methods
2.1. Protein puriﬁcation and analysis
Fibrinogen was puriﬁed by ammonium sulphate precipitation [17]
from Li heparin plasma that had been used for acute phase assessment
of C reactive protein (CrP). After reduction (4 h at 37 °C) in 8 M urea,
0.1 M Tris/HCl pH 8, 15 mM dithiothreitol individual ﬁbrinogen chains
were isolated by reverse phaseHPLC on a Jupiter C-4 (25 × 0.46 cm) col-
umn (Phenomenex) [8,17]. Approximately 150 μg of ﬁbrinogen was
injected, and ~200 μl of individual Bβ and γ peak crests was collected
and 20 μl directly injected into a VG Platform quadrupole analyser at
10 μl/min. The probe was charged at +3000 V, and the electrospray
source was maintained at 60 °C. The mass range 1050–1600 m/z was
scanned with a cone ramp of 50–70. Up to 120 scans were averaged
and transformed using Mass-Links software [8,17].
2.2. Glycosidase digestion
Puriﬁed ﬁbrinogen (50) μg was taken up in 50 μl of 50 mM Tris/HCl
pH 7.5 containing 10mMEDTA, 1%NP-40 and incubated (16 h, at 30 °C)
with 5 U of N-glycosidase F (Roche). One microlitre was analysed by
reducing SDS–PAGE to conﬁrm cleavage of the oligosaccharide and the
remainder reduced, as above, and subjected to reverse phase HPLC to
isolate the Bβ and γ chains for mass analysis.
For the removal of galactose from non-reducing termini, 50 μg of
ﬁbrinogen was taken up in 50 μl 50 mM phosphate buffer pH 7,
1 mM Mg Cl2 1.5 mM dithiothreitol and 1 μg of Streptococcus
pneumoniae β1,4 galactosidase (Calbiochem) added. Digests were
incubated overnight at 37 °C, and the ﬁbrinogen precipitated with
ammonium sulphate prior to reduction, reverse phase HPLC and mass
spectrometry. Of note, neither the Roche or the Sigma β1,4 galactosi-
dase from Escherichia coli were capable of cleaving the terminal
galactose from ﬁbrinogen. Although all three enzymes rapidly cleaved
the reporter chromogenic substrate 5-bromo-4-chloro-indolyl-β-D-
galactopyranoside (X-Gal), only the Streptococcus pneumoniae enzyme
was able to cleave the terminal Gal residues from ﬁbrinogen.
2.3. Isolation of glycopeptides
Ten micrograms of Fibrinogen was boiled (5 min) in 1 ml 50 mM
NH4HCO3, 0.2 mg trypsin added, and the digest incubated for 24 h at
37 °C. After centrifugation, the supernatantwas applied to a 1mlHiTrapConconavilin A Sepharose 4B column (GE Healthcare) equilibrated in
0.1 M NH4HCO3, pH 6.7, 1 mM MnCl2 and 1 mM CaCl2.The column
was washed with 0.1 M NH4HCO3 pH 6.7, and the unbound fraction
was collected. After further washing with 5-column volumes, the
bound fraction was eluted with 0.1 M αmethyl glucoside. Bound and
unbound fractions were dried and taken up in 0.5 ml 0.1% HCOOH.
Fractions (10 μl) were then diluted into 50% acetonitrile 0.1% HCOOH
and analysed by direct injection into the electrospray source.
3. Results
3.1. Patient
The principal patient examined here was a 58-year-old heavy
smoker diagnosed as having an abscess on his lung. He had been ill for
2 weeks prior to our “day 1” plasma sample, at which time he had a
CrP of 298 mg/L. Plasma samples were obtained daily over the subse-
quent 8 days after which time his CrP had fallen to 160mg/L. Fibrinogen
was puriﬁed from each of the plasmas, and the individual chains
isolated by reverse phase HPLC prior to analysis by electrospray
ionisation mass spectrometry (ESI MS).
3.2. Fibrinogen Bβ and γ chain analysis
Examination of γ chains from normal and quiescent state control
plasma with a CrP of b5 mg/L showed the expected major monosialo
isoform at 48,375 Da together with its disialo isoform (+291) at
48,668 Da [5,8,18] (Fig. 1). Patient chains showed a very different
pattern with peaks at 48,216, 48,375 and 48,666 Da. The dominant
48,216 species was 159 Da less than the dominant control isoform
possibly reﬂecting loss of hexose (−162 Da) from the oligosaccharide,
because if a truncation of the protein was responsible for the mass
decrease, then the disialo isoform at+291Dawould also have a similar
(−162 Da) companion peak. Kinetically, the amount of what we have
termed des-Gal γ decreased progressively from 55% to 39% during the
acute phase recovery from a CrP of 298 to 160 mg/L, and the amount
of disialo γ increased from 8% to 16% of the total over the 8 days of
recovery.
Analysis of Bβ chains also showed the familiar mono and disialo
isoforms (+291 Da) at 54,198 and 54, 499 Da [5,8,17,18]. Patient Bβ
chains, on the other hand, were composed of additional lower mass
peaks at −160 Da and a further component at 199 Da lower again.
These were surmised to represent des-Gal and desNAcGlc-Gal, which
would have successive mass decreases of 162 and 203 Da, respectively.
The amount of Des-Galβ decreased from 35% to 20% and desNAcGlc-Gal
from 12% to 5%, while disialo Bβ chains increased from 12% to 20 % over
the 8 days of sampling.
Themeasured mass decrease of the γ chain (−159 Da) could corre-
spond to loss of its N-terminal Tyr (−163 Da) or to loss of a terminal
galactose residue (162 Da) from its asialo oligosaccharide fork. Tryptic
peptidemaps of patientγ chainswere however very similar to controls;
speciﬁcally, therewere no differences in intensities of ions derived from
either the N- or C-terminal peptides (not shown).
3.3. Digestion with N-glycosidase F
To conﬁrm the carbohydratemoiety as the source of the acute phase
variation, ﬁbrinogenwas incubatedwith N-glycosidase F, which cleaves
the glycosidic bond between Asn and NAcGlc, and the individual chains
isolated by HPLC. Theoretically, this should involve decreases of 1,915
and 2,206 Da for the mono and disialo isoforms, respectively, and the
production of a single unadorned protein product. This is exactly what
was observed in the control γ chains, where mass decreases of 1,919
and 2,202 Da yielded a polypeptide of mass 46,474 Da (Fig. 2). The
three different components of the patient γ chains were similarly
normalised down to a single naked polypeptide of 46,472 Da,
Fig. 1. Transformed ESI spectra of isolated γ (left panel) and Bβ chains (right panel) showing normal control (bottom pane) and selected chains from days 1 to 8 of the acute phase
response. The displayed masses are the averages of the eight measurements with standard errors. Mass differences from the base peak (the monosialo chain) are also shown together
with CrP values in mg/mL (far right) for the various days. Spectra of patient γ chains showed the major isoform had a mass decrease of 159 Da, while patient Bβ chains also showed a
shift to lower masses with novel signals at−160 and−199 Da, most probably corresponding to progressive loss of Gal (162 Da) and NAcGlc (203 Da) from the asilo branch of the
oligosaccharide.
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its oligosaccharide side chain. Examination of Bβ chains from the control
also showed themono and disialo isoforms had decreased by 1,921 and
2,217 Da to give a 52,284 polypeptide after N-glycosidase F treatment.
Similarly, the four isoforms (desNAcGlc-Gal, des-Gal, monosialo and
disialo) of the patient Bβ chains were normalised to a single 53,289 Da
protein (Fig. 2).
3.4. Digestion with β1-4 galactosidase
In order to establish the precise cause of the Bβ and γ chain varia-
tion, patient and control ﬁbrinogenwere incubatedwith β1-4 galactosi-
dase from Streptococcus pneumoniae. This exoglycosidase hydrolyses
non-reducing terminal β1-4 linked galactose residues. As only theFig. 2. Transformed ESI spectra of γ (left panel) and Bβ chains (right panel) isolated from ﬁbrino
(CA) incubation, and day 2 patient ﬁbrinogen before (PB) and after (PA) incubation. Measured
The normalisation of patient chains on incubation with the endoglycosidase establishes the camonosialo isoformhas such a terminal, theminor disialo isoform should
remain unaffected by galactosidase, but both the control and the patient
chains should normalise to the patient pattern. This is precisely what
was observed. Control γ chains decreased from 48,390 to 48, 219 Da
to match the aberrant 48,216 Da γ chain of the patient, while only the
48,370 Da chain of the patient was hydrolysed (Fig. 3). Similar results
were obtained for the Bβ chain with the monosialo control chain
decreasing to 54,031 Da and matching the patient chains at 54,035 Da
(not shown).
3.5. Glycopeptide isolation and peptide analysis
To conﬁrm the absence of galactose as the cause of Bβ and γ chain
acute phase heterogeneity, tryptic glycopeptides were isolated bygen before and after incubationwith N-glycosidase F. Control before (CB) and control after
mass differences are indicated in comparison to the expected shifts of 1,919 and 2,206 Da.
rbohydrate moieties as the source of the acute phase mass variation.
Fig. 3. Transformed ESI spectra of γ chains isolated from ﬁbrinogen before and after incu-
bation with Streptococcus pneumoniae β1,4-galactosidase. Control before (CB) and control
after (CA) incubation; patient before (PB) and patient after (PA) incubation. Only the
monosialo isoform is susceptible to hydrolysis as the 48,216 and 48,662 Da species lack
terminal galactose residues.
Fig. 4. ESI tryptic peptide maps. (A) Conconavalin-A Sepharose bound glycopeptides from diges
its disialo isoform (+SA) are indicated;Na+andK+adducts are seen in addition to theprotonat
γ5 and γ4-5, with (+SA) or without one sialic acid. (B) Tryptic digest of isolated ﬁbrinogen γ
glycopeptides derived ions are labelled. The principal species detectedwereM+3HandM+2
γ4-5+2(2019) at 1292 and1938m/z, respectively, that reﬂect the loss of galactose (162Da). Sim
the 1767 and 1848 ions. (C) Structure of the principal γ4-5 biantennary glycopeptide that ter
NAcGlc.
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withαmethylglucoside. ESIm/zmaps conﬁrmed that both oligosaccha-
ride chains were exclusively of the biantennary type. Doubly and triply
charged ions of β41 and γ5, the expected glycopeptides, were detected
together with companion species lacking one sialic acid residue
(Fig. 4A). In addition, a γ4-5 peptide was also detected; its presence
being the result of the negative impact of the ﬂanking aspartic acid
residues on cleavage at Lys38. Na+ and K+ ions of γ5 (1239 and
1245 m/z) were detected along with the fully protonated 1232 ion
and similar triplet ions were seen for β41+3 at 1270, 1277 and
1282 m/z. The structure of the γ4-5 peptide that gives rise to the 1346
and 2019 ions is shown in Fig. 4 panel C. If as, surmised, this peptide
lost galactose (162 Da), then companion ions would be expected at
1292 and 1938 m/z. Surprisingly, these ions were not present, and
similarly there was no evidence of loss of galactose from β41 in this
concanavalin-A puriﬁed peptide fraction.
Initially, this seemed to negate the ﬁnding that loss of galactose was
the underlying cause of the acute phase variation, and to resolve this
paradox, we examined total digests of individually isolated ﬁbrinogen
chains that had no prior lectin afﬁnity isolation (Fig. 4B). Here the
same pattern of γ ions was seen together with expected non-
glycopeptides ions such as 2161 (γ8), 1418 (γ32), 1547 (γ42) or 1895
(γ36). More importantly, the predicted new glycopeptide ions were
seen at 1292, 1938 and 1767 m/z corresponding to γ4-5 and γ5
peptides lacking galactose. Notably, these were of similar intensity to
their full-length companion peptides (1346, 2019, 1848 respectively),
indicating that day 7 plasma contained 50% des-Gal γ chains. This was
in excellent agreementwith estimates of 46% from analysis of the intact
ﬁbrinogen chains from day 7 plasma (Fig. 1).
From our previous mass analysis of intact γ chains from over 200
individuals with hypo- or dysﬁbrinogenemia (and assumed normal
CrP), we have rarely see peaks of over ~5% in the des-Gal γ position
at−162 Da. In an attempt to conﬁrm the loss of galactose related to a
sustained acute phase response, we examined an additional nine
plasma samples from another individual with high CrP values. The
patient in this case was a 57-year-old alcoholic with a sustainedts of total ﬁbrinogen from patient plasma. TheM+3 andM+ 2 ions of β41 together with
ed ion (H+) at 1277, 1280 and1270, respectively. Theγ chain glycopeptidewasdetected as
chains from day 4 patient plasma; the insert shows repeat high mass scan of same digest,
H ions ofγ5 and γ4-5. Most signiﬁcantly, therewere companion ions toγ4-5+3(1346) and
ilarly, the loss of ~50% of the galactose fromγ5+2 is evidenced by the similar amplitudes of
minates in sialic acid and galactose; instead, the variant peptide terminates at the SA and
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415 to 190 mg/L over a 10-day period. Over the ﬁrst 8 days, his
des-Gal γ ﬁbrinogen progressively rose from 15% to 42% of the total
and then decreased to 34% by day 10.
4. Discussion
Here we have shown that, unlike α1 antitrypsin [10], the oligosac-
charide side chains of ﬁbrinogen remain exclusively of the biantennary
type during an acute phase response. Instead of the increased branching
seen in antitrypsin, post-translational variation of ﬁbrinogen involves
decreases in the length of one of the γ and Bβ chain forks (Fig. 4C).
Mass analysis of isolated intact chains suggested loss of galactose was
the underlying cause of the−162 Damass variations, and this was sup-
ported by digestion with N-glycosidase F, which normalised the acute
phase and quiescent ﬁbrinogen to the same mass of 46,474 for the γ
and 52,289 Da for the Bβ chain (Fig. 2). Incubations with Streptococcus
pneumoniae β1,4-galactosidase further conﬁrmed that the absence of
galactose underpinned the structural difference between the quiescent
and the inﬂammatory state (Fig. 3).
Despite these clear ﬁndings, maps of glycopeptides isolated by
afﬁnity chromatography on conconavalin-A Sepharose failed to show
any glycopeptides that lacked galactose. On the other hand, maps of
non-lectin-fractionated γ chain peptides showed equal portions of the
γ5 (and γ4-5) peptide with and without their terminal galactose. The
conclusion from this can only be that the modiﬁcation itself decreased
conconavalin-A afﬁnity and that the des-Gal peptides eluted in the
unbound, or buffer-wash fractions. Examination of the unbound
fraction (not shown) showed no glycopeptides, suggesting the des-Gal
peptides eluted in the discarded low stringency washes. The principal
requirement for lectin binding would seem to be the presence of
cis-diols on the sugar residues, and these are provided by mannose
and galactose residues, which have cis-hydroxyl groups in the 2′3′
and 3′4′ positions, respectively. Loss of one galactose residue should
therefore reduce, but probably not prevent lectin binding, resulting
in exclusion of des-Gal peptides from either the bound or unbound
fraction.
In the sustained inﬂammatory response examined here, des-Gal γ
ﬁbrinogen became the dominant γ chain species present exceeding
55% of the total (Fig. 1). Moreover, in the case of the Bβ chain, there
was additional fraying of the carbohydrate structure because in addition
to des-Gal β, which accounted for 35%, substantial amounts (12%) of
further truncated des-NAcGlc-Gal was also present.
Alterations in the oligosaccharide conﬁguration of plasma glycopro-
teins can have a profound impact on haemostasis [16]. As an example
the physiological variant, antithrombin β, which lacks its Asn135 oligo-
saccharide, has a higher heparin afﬁnity than antithrombinα [19]. So al-
though the β isoformmakes up only 5–10% of the total, it is actually the
major physiological regulator of thrombin activity [20]. Small changes
in carbohydrate structures can also have a signiﬁcant impact on circula-
tory clearance. For example (in rats), the half-life of von Willebrand
factor decreases from 240 to 5 min after incubation with neuramini-
dase, which unmasks the underlying Gal residues and triggers uptake
of the protein by the asialoglycoprotein receptor [21]. Also, it has been
shown that the inactivation of the sialyltransferase that adds CMP-
activated acetylneuraminic acid into penultimate Gal residues (ST3
Gal-IV) signiﬁcantly increases von Willebrand Factor uptake by this
receptor [21,22].
What impact might the loss Gal have on ﬁbrinogen? First, it is well
established that a decrease in the sialic acid content lessens the electro-
static repulsion between ﬁbrin monomers during polymerisation [6,9,
23]. Hence, acute phase ﬁbrinogen would have a shorter clotting time
because if there is no galactose terminal available, then the outer sialic
acid cannot be attached by CMP-NAcNeu Gal transferase. As it turns
out, this is a desirable outcome because part of the acute phase response
is to protect against the threat of haemorrhage.The second predictable impact on ﬁbrinogen would be an extended
half-life and ramped up plasma concentration because ﬁbrinogen is
normally removed from circulation not only by ﬁbrinolytic consump-
tion but also by the hepatic asialoglycoprotein receptor. What this
receptor actually recognises, however, is two exposed Gal residues,
and clearly if there is no Gal on one branch, then the receptor can
never “see” two residues. This is not to say the half-life will become
inﬁnite because in the 340 kDa ﬁbrinogen molecule, there are a total
of four biantennary oligosaccharides any one of which can reveal two
Gal residues and provoke turned over. In support of this, we have
analysed many hundreds of ﬁbrinogen samples by ESI MS and never
observed a single incidence of a circulatory ﬁbrinogen molecule lacking
both sialic residue.
5. Conclusion
In conclusion, in an acute phase, the carbohydrate structure of
ﬁbrinogen becomes modiﬁed in such a way as to increase the proteins
concentration and the rate of ﬁbrin polymerisation and clot formation,
helping to maintain haemostasis.
Transparency document
The Transparency document associated with this article can be
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